top of page
  • Writer's pictureFutureMeds

FutureMeds Celebrates its Frankfurt Site Opening with an Exclusive Conference

FutureMeds Frankfurt officially opened its doors after an exclusive conference exploring the direction of research in Germany.  

Dr Radoslaw Janiak gives a brief overview of FutureMeds and how this growing site network can drive progress in research

To mark FutureMeds Frankfurt’s site opening and demonstrate the network’s dedication to advancing healthcare, the FutureMeds Germany team, led by Ninon Armbrust, organised an exclusive conference on June 12 to discuss the country’s current research realities.  

This conference, which attracted a diverse group of stakeholders, including researchers, healthcare professionals, and industry experts, aimed to encourage meaningful discussions and explore how dedicated research sites, decentralised trial solutions, and digital recruitment can drive meaningful, lasting change in research.  


“Germany as a study location is especially close to my heart, and I was thrilled to see the rich exchange of ideas between study sites, CROs, sponsors, and clinical research companies. The feedback we received was outstanding, and it’s incredibly rewarding to hear how much everyone valued the discussions and presentations.” 

- Ninon Armbrust, Head of Sites at FutureMeds Germany  


The event was opened by Ninon, followed by Dr Radoslaw Janiak, the CEO of FutureMeds, who offered attendees a quick introduction to the company and outlined the opportunities and solutions the site network offers for clinical research. 

The next speech, delivered by Dr. Torsten Sernau, dived into the perfect storm facing the country’s research and healthcare scene: increasing protocol complexity, a large percentage of physicians going part-time, and close to 45% of them retiring, increasing pressure on conventional sites who also need to provide care for patients.   

Iwona Tongbhoyai showcases the benefits of decentralised trials and how they can help overcome resource constraints and patient challenges

To explore various resource constraint mitigations, Iwona Tongbhoyai, Chief Client Solutions Officer at FutureMeds, briefly talked about the benefits of DCT solutions and the challenging TAs they can support. 

Nele Brennecke provides an insightful overview of the advantages of leveraging digital approaches in patient recruitment and retention

Shortly after, Nele Brennecke, Head of Patient Engagement Germany, shared insights into the benefits of leveraging digital technology to boost recruitment and retention of patients. 


Investigator Views on the State of Research in Germany 


For the second part of the conference, the audience welcomed on stage the panelists: Dr. med. Peter Hahn, PI, Pl Dr. med. Kerstin Sturm, PI,  Dr. med. Torsten Sernau, Doris Wiegel, Director of Operational Affairs (CRO) and Dr. Oliver Deuster, Head of Clinical Monitoring at University Medical Center Mainz. 

Panelists: Dr. med. Peter Hahn, PI, Pl Dr. med. Kerstin Sturm, PI, Dr. med. Torsten Sernau, Doris Wiegel, Director of Operational Affairs (CRO) and Dr. Oliver Deuster

The experienced panellists with insights into the German clinical trial realities explored: 

  • How to make clinical trials even more attractive for patients 

  • Everyday life and challenges of a PI 

  • Differences between dedicated sites, medical practices and clinics 

  • One other topic that came up was the reputation of clinical trials in society, what we could do to improve it and who could/should drive this change 


FutureMeds Frankfurt Site Opening 


“Building on FutureMeds' and our Berlin’s site reputation, experience and outstanding standard of quality, opening a second site in the Rhein-Main, a world-leading life sciences cluster, made perfect sense. Operating in this region will enable FutureMeds to build stronger ties with the local industry and increase patient access to new treatments.”  

- Dr Radoslaw Janiak, CEO at FutureMeds 


With the new dedicated research site in Frankfurt, FutureMeds aims to tap into the rich tapestry of the region's academic, industrial, and regulatory presence in life sciences, build ties with diverse populations, and work with experienced investigators to boost patient access to trials and new treatments. 

Dr. med. Peter Hahn, Dr Radoslaw Janiak and Ninon Armbrust at the ribbon cutting ceremony for FutureMeds Frankfurt, the newest Dedicated Research site in the portfolio

“The first projects, which will start soon after the official opening and conference, clearly show how urgently we need dedicated study sites in Germany. A large percentage of physicians and nurses in Germany are nearing retirement, and this will have an impact on patient care and clinical trial capacity across the country,” commented Ninon Armbrust, Head of Sites at FutureMeds Germany   

We extend our heartfelt thanks to all the attendees, speakers, and organisers who made this event successful. We look forward to continuing our work in Germany and beyond. 

About FutureMeds   


Specialising in conducting clinical trials, FutureMeds is the 1st European Independent Dedicated DCT Site Network offering high levels of traditional and Decentralised Clinical Trial capabilities across the whole network and home nursing solutions in 18 European countries.  


FutureMeds is driven by a purpose to connect a global healthcare community and help bring quicker access to life-changing medications and therapies to all those who need them worldwide.  


FutureMeds’ Dedicated Research Site (DRS) teams serve as the company’s service foundation. DRS team’s capabilities help pharmaceutical companies and contract research organisations accelerate study timelines, streamline processes, lower costs, improve data quality and ultimately help speed up drug development and patient access to new treatments.  


FutureMeds @home, the company’s Decentralised Clinical Trial solution, provides pharmaceutical companies, contract research organisations and other partners with tools, teams & support, enabling them to simplify patient access to trials and boost recruitment, engagement and retention.  


Through its acquisitions, partnerships and a strategic focus on patient experience, FutureMeds brings opportunities to diverse European patient populations to participate in clinical research under the medical supervision of qualified physicians and health care professionals.  



Follow us on LinkedIn  


Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible. 



Commenting has been turned off.
bottom of page